Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models
Abstract When breast cancer patients start to exhibit resistance to hormonal therapy or chemotherapy, the mTOR inhibitor everolimus can be considered as an alternative therapeutic agent. Everolimus can deregulate the PI3K/AKT/mTOR pathway and affect a range of cellular functions. In some patients, t...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2019
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/c7eb9d6b994340dfae24eaf48c223d35 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|